1. Key Insights 2. Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer Epidemiology Overview at a Glance 2.1. Total Epidemiology Distribution of HR-positive/HER2-negative in 2017 2.2. Total Epidemiology Distribution of HR-positive/HER2-negative in 2028 3. Disease Background and Overview: Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer 3.1. Introduction 3.2. Types of Breast Cancer 3.2.1. Subtypes of Breast Cancer 3.2.2. Molecular Subtypes of Breast Cancer 3.3. Estrogen Receptor (ER)-Positive Breast Cancer 3.3.1. Estrogen Receptor 3.3.2. Estrogen Receptor 1 Mutations 3.4. Metabolic Pathway of Estrogen Receptor (ER)-Positive Breast Cancer 3.4.1. Role of Estrogen Receptor Alpha (ERα) in Regulating Breast Cancer Metabolism 3.5. Symptoms of HR-Positive Breast Cancer 3.6. Risk Factors of Estrogen Receptor (ER)-Positive Breast Cancer 3.7. Diagnosis of Estrogen Receptor (ER)-Positive Breast Cancer 3.8. Diagnostic Guidelines for Estrogen-Receptor (ER) Positive Breast Cancer 3.8.1. American Society of Clinical Oncology (ASCO) 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Population and Forecast Parameters 4.3. Total Incidence of Breast Cancer in the 7MM 4.4. Diagnosed Incidence of HR+/HER2- post-menopausal early stage Breast Cancer in the 7MM 4.5. Diagnosed Incidence of HR+/HER2- post-menopausal advanced and metastatic stage Breast Cancer in the 7MM 4.6. Total Diagnosed Incidence of HR+/HER2- post-menopausal Breast Cancer in the 7MM 5. Country Wise-Epidemiology of Hormone Receptor (HR) Positive Breast Cancer 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Total Incidence of Breast Cancer in the United States 5.1.3. Incidence of Breast Cancer Cases by Menopausal Status in the United States 5.1.4. Stage-Specific Incidence of Breast Cancer in Post-Menopausal Women in the United States 5.1.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the United States 5.1.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in the United States 5.1.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in the United States 5.2. EU5 Countries 5.3. Germany 5.3.1. Assumptions and Rationale 5.3.2. Total Incidence of Breast Cancer in Germany 5.3.3. Incidence of Breast Cancer Cases by Menopausal Status in Germany 5.3.4. Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Germany 5.3.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Germany 5.3.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in Germany 5.3.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in Germany 5.4. France 5.4.1. Assumptions and Rationale 5.4.2. Total Incidence of Breast Cancer in France 5.4.3. Incidence of Breast Cancer Cases by Menopausal Status in France 5.4.4. Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in France 5.4.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in France 5.4.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in France 5.4.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in France 5.5. Italy 5.5.1. Assumptions and Rationale 5.5.2. Total Incidence of Breast Cancer in Italy 5.5.3. Incidence of Breast Cancer Cases by Menopausal Status in Italy 5.5.4. Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Italy 5.5.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Italy 5.5.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in Italy 5.5.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in Italy 5.6. Spain 5.6.1. Assumptions and Rationale 5.6.2. Total Incidence of Breast Cancer in Spain 5.6.3. Incidence of Breast Cancer by Menopausal Status in Spain 5.6.4. Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Spain 5.6.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Spain 5.6.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause Cases by Molecular Subtype in Spain 5.6.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause Cases by Molecular Subtype in Spain 5.7. The United Kingdom 5.7.1. Assumptions and Rationale 5.7.2. Total Incidence of Breast Cancer in the United Kingdom 5.7.3. Incidence of Breast Cancer Cases by Menopausal Status in the United Kingdom 5.7.4. Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the United Kingdom (2017–2028) 5.7.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the United Kingdom 5.7.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in the United Kingdom 5.7.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in the United Kingdom 5.8. Japan 5.8.1. Assumptions and Rationale 5.8.2. Total Incidence of Breast Cancer in Japan 5.8.3. Incidence of Breast Cancer Cases by Menopausal Status in Japan 5.8.4. Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Japan (2017–2028) 5.8.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the Japan 5.8.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in Japan 5.8.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in Japan 6. Appendix 6.1. Report Methodology 7. DelveInsight Capabilities 8. Disclaimer 9. About DelveInsight

Table 1: Total Incidence of Breast Cancer in the 7MM (2017–2028) Table 2: Diagnosed Incidence of HR+/HER2- post-menopausal early stage Breast Cancer in the 7MM (2017–2028) Table 3: Diagnosed Incidence of HR+/HER2- post-menopausal advanced and metastatic stage Breast Cancer in the 7MM Table 4: Total Diagnosed Incidence of HR+/HER2- post-menopausal Breast Cancer in the 7MM Table 5: Total Incidence of Breast Cancer in the United States (2017–2028) Table 6: Incidence of Breast Cancer by Menopausal Status in the United States (2017–2028) Table 7: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the United States (2017–2028) Table 8: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the United States (2017–2028) Table 9: Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in the United States (2017–2028) Table 10: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in the United States (2017–2028) Table 11: Incidence of Breast Cancer in Germany (2017–2028) Table 12: Incidence of Breast Cancer by Menopausal Status in Germany (2017–2028) Table 13: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Germany (2017–2028) Table 14: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Germany (2017–2028) Table 15: Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype Cases in Germany (2017–2028) Table 16: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype Cases in Germany (2017–2028) Table 17: Total Incidence of Breast Cancer in France (2017–2028) Table 18: Incidence of Breast Cancer by Menopausal Status in France (2017–2028) Table 19: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in France (2017–2028) Table 20: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in France (2017–2028) Table 21: Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in France (2017–2028) Table 22: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in France (2017–2028) Table 23: Total Incidence of Breast Cancer in Italy (2017–2028) Table 24: Incidence of Breast Cancer by Menopausal Status in Italy (2017–2028) Table 25: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Italy (2017–2028) Table 26: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Italy (2017–2028) Table 27: Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in Italy (2017–2028) Table 28: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in Italy (2017–2028) Table 29: Total Incidence of Breast Cancer in Spain (2017–2028) Table 30: Incidence of Breast Cancer by Menopausal Status in Spain (2017–2028) Table 31: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Spain (2017–2028) Table 32: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Spain (2017–2028) Table 33: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype in Spain (2017–2028) Table 34: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype in Spain (2017–2028) Table 35: Total Incidence of Breast Cancer in the United Kingdom (2017–2028) Table 36: Incidence of Breast Cancer by Menopausal Status in the United Kingdom (2017–2028) Table 37: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the UK (2017–2028) Table 38: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the UK (2017–2028) Table 39: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype in the United Kingdom (2017–2028) Table 40: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype in the United Kingdom (2017–2028) Table 41: Total Incidence of Breast Cancer in Japan (2017–2028) Table 42: Incidence of Breast Cancer by Menopausal Status in Japan (2017–2028) Table 43: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Japan (2017–2028) Table 44: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the Japan (2017–2028) Table 45: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype in Japan (2017–2028) Table 46: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype in Japan (2017–2028) Figure 1: Molecular Subtypes of Breast Cancer Figure 2: Working of Estrogen Receptor Figure 3: Schematic Structure of the Estrogen Receptor (ER) Depicting Six Domains. Figure 4: ER pathway and mechanisms of resistance. Estrogen-bound estrogen receptor (ER), in association with a variety of coactivators and co-repressors, exerts its classical genomic action as a transcription factor through the estrogen response element (ERE) of target genes. Figure 5: Metabolism of Estrogen Receptor-Positive Breast Cancer Figure 6: Lifestyle-related Breast Cancer Risk Factors Figure 7: Diagnosis of ER-Positive Breast Cancer Figure 8: Assays for Measuring Estrogen and Progesterone Receptor Figure 9: Essential Elements Required for Accurate Testing of ERa And PGr Status In Breast Cancer by Immunohistochemistry. Figure 10: Total Incidence of Breast Cancer in the 7MM (2017–2028) Figure 11:Diagnosed Incidence of HR+/HER2- post-menopausal early stage Breast Cancer in the 7MM (2017–2028) Figure 12: Diagnosed Incidence of HR+/HER2- post-menopausal advanced and metastatic stage Breast Cancer in the 7MM Figure 13: Total Diagnosed Incidence of HR+/HER2- post-menopausal Breast Cancer in the 7MM Figure 14: Total Incidence of Breast Cancer in the United States (2017–2028) Figure 15: Incidence of Breast Cancer Cases by Menopausal Status in the United States (2017–2028) Figure 16: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the United States (2017–2028) Figure 17: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the United States (2017–2028) Figure 18: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype in the United States (2017–2028) Figure 19: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype in the United States (2017–2028) Figure 20: Total Incidence of Breast Cancer in Germany (2017–2028) Figure 21: Incidence of Breast Cancer Cases by Menopausal Status in Germany (2017–2028) Figure 22: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Germany (2017–2028) Figure 23: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Germany (2017–2028) Figure 24: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype Cases in Germany (2017–2028) Figure 25: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype Cases in Germany (2017–2028) Figure 26: Total Incidence of Breast Cancer in France (2017–2028) Figure 27: Incidence of Breast Cancer Cases by Menopausal Status in France (2017–2028) Figure 28: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in France (2017–2028) Figure 29: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in France (2017–2028) Figure 30: Diagnosed Incidence of early Stage Breast Cancer in Post-Menopausal by Molecular Subtype in France (2017–2028) Figure 31: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype in France (2017–2028) Figure 32: Total Incidence of Breast Cancer in Italy (2017–2028) Figure 33: Incidence of Breast Cancer Cases by Menopausal Status in Italy (2017–2028) Figure 34: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Italy (2017–2028) Figure 35: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Italy (2017–2028) Figure 36: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype in Italy (2017–2028) Figure 37: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype in Italy (2017–2028) Figure 38: Total Incidence of Breast Cancer in Spain (2017–2028) Figure 39: Incidence of Breast Cancer by Menopausal Status in Spain (2017–2028) Figure 40: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Spain (2017–2028) Figure 41: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Spain (2017–2028) Figure 42: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal Cases by Molecular Subtype in Spain (2017–2028) Figure 43: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal Cases by Molecular Subtype in Spain (2017–2028) Figure 44: Total Incidence of Breast Cancer in the United Kingdom (2017–2028) Figure 45: Incidence of Breast Cancer Cases by Menopausal Status in the United Kingdom (2017–2028) Figure 46: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the UK (2017–2028) Figure 47: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the UK (2017–2028) Figure 48: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype in the United Kingdom (2017–2028) Figure 49: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype in the United Kingdom (2017–2028) Figure 50: Total Incidence of Breast Cancer in Japan (2017–2028) Figure 51: Incidence of Breast Cancer Cases by Menopausal Status in Japan (2017–2028) Figure 52: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Japan2017–2028) Figure 53: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the Japan (2017–2028) Figure 54: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype in Japan (2017–2028) Figure 55: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype in Japan (2017–2028)